Quotes 5-day view Delayed Nasdaq
05/11/2022
05/12/2022
05/13/2022
05/16/2022
05/17/2022
Date
0.5701(c)
0.6(c)
0.6999(c)
0.6325(c)
0.6446 Last
821 163
163 104
136 370
347 083
146 828 Volume
-6.85% +5.24% +16.65% -9.63% +1.91% Change
Estimated financial data (e) (USD)
Sales 2022
-
-
-
Net income 2022
-78,0 M - -
Net cash position 2022
58,7 M - -
P/E ratio 2022
-0,63x
Yield 2022
-
Sales 2023
16,7 M - -
Net income 2023
-72,4 M - -
Net Debt 2023
15,8 M - -
P/E ratio 2023
-0,83x
Yield 2023
-
Capitalization
42,8 M 42,8 M -
EV / Sales 2022
-
EV / Sales 2023
3,52x
Nbr of Employees
40
Free-Float
88,6%
Aptinyx, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of synthetic small molecules for the treatment of brain and nervous system disorders. The Company is targeting and modulating N-methyl-D-aspartate receptors (NMDArs), which are focused on brain and nervous system. It has three product candidates in clinical development in central nervous system...
All news about APTINYX INC.
05/12 TRANSCRIPT : Aptinyx Inc., Q1 2022 Earnings Call, May 12, 2022CI
05/12 APTINYX INC. Management's Discussion and Analysis of Financial Condition and Results
o.. AQ
05/12 Aptinyx Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
05/12 Aptinyx Reports First Quarter 2022 Financial Results and Highlights Recent Clinical Pro.. BU
04/29 Aptinyx Presents Preclinical Data on NYX-783 in Models of PTSD at 2022 Society of Biolo.. BU
04/29 Aptinyx Inc. Presents Preclinical Data on NYX-783 in Models of PTSD at 2022 Society of .. CI
04/27 Aptinyx to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022 BU
04/21 SVB Leerink Adjusts Aptinyx Price Target to $4 From $10, Maintains Outperform Rating MT
04/20 Aptinyx Announces Publication in Molecular Psychiatry Demonstrating Reduction of Sponta.. BU
04/20 Aptinyx Inc. Announces Publication in Molecular Psychiatry Demonstrating Reduction of S.. CI
04/19 APTINYX INC. : Other Events (form 8-K)AQ
04/19 Aptinyx Inc Announces Temporarily Paused the Initiation of its Phase 2b Study of the 15.. CI
04/14 HC Wainwright Adjusts Price Target on Aptinyx to $2 From $8, Reiterates Buy Rating MT
04/08 BMO Capital Adjusts Price Target for Aptinyx to $6 From $12, Maintains Outperform Ratin.. MT
04/08 Cantor Fitzgerald Lowers Aptinyx's Price Target to $5 From $11, Maintains Overweight Ra.. MT
News in other languages on APTINYX INC.
Analyst Recommendations on APTINYX INC.
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends APTINYX INC.
Short Term Mid-Term Long Term Trends Bearish Bearish Bearish
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
BUY
Number of Analysts
8
Last Close Price
0,63 $
Average target price
5,33 $
Spread / Average Target
743%
Please enable JavaScript in your browser's settings to use dynamic charts.
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Report
